帕妥昔单抗销售预测及市场规模分析（2034 年）

推动帕妥索汀成长的关键因素

1. 扩大市场占有率并增加新患者数量

• Paltusotine 被定位为治疗肢端肥大症的潜在First-in-Class口服疗法，而目前市场主要由长效注射以生长抑制素受体配体 (SRL) 主导。
• 内分泌科医生的浓厚兴趣表明未来有潜力吸引新患者，尤其是在寻求慢性注射疗法替代方案的患者群体中。
• 预计每日一次的口服给药方式将减轻治疗负担并提高依从性，核准后可望迅速广泛应用。
• Crinetics Pharmaceuticals 专注于口腔疾病管理的商业策略和医生教育工作有望促进该领域的快速发展。

2. 扩展至主要适应症

• 肢端肥大症（主要适应症）：帕妥索汀正在开髮用于治疗需要生化控制的肢端肥大症患者，包括先前接受过注射西罗莫司治疗的患者。
• 维持治疗：对于已达到生化控制的患者，该药物有可能成为有利的维持治疗选择，并且一旦病情稳定，该药物可以取代注射药物。
• 广泛的肢端肥大症患者群体：如果核准，帕妥索汀有可能用于广泛的患者群体，包括那些无法充分或耐受注射疗法的患者。
• 研发管线和生命週期机会包括更早用于治疗和更长期的疾病管理策略。

3. 地理扩张

• Paltusotine 正在开发中，旨在实现全球商业化，最初的目标是美国和欧洲等主要内分泌市场。
• 亚太地区具有长期成长潜力，这得益于脑下垂体疾病诊断率的提高和获得专业内分泌护理的机会改善。
• 未来区域扩张预计将透过与当地监管机构的合作以及在内分泌专科领域的伙伴关係来实现。

4. 新适应症的核准

• 成功获得监管部门对肢端肥大症的核准，将大大扩展该疾病的治疗选择，而过去十年来，该领域的创新一直很有限。
• 帕妥索汀独特的口服特性有可能重塑标准治疗流程，并使其能够随着时间的推移扩展到更广泛的患者亚群。
• 随着更多监管里程碑的达成以及在美国以外市场提交申请，未来收入来源有望进一步多元化。

5.肢端肥大症交易量强劲成长

• 肢端肥大症是一种慢性终身疾病，需要持续治疗，因此预计治疗需求将保持稳定。
• 患者和医生对注射疗法的不满，正在催生对口服替代疗法的潜在需求，这为口服疗法提供了很高的普及潜力。
• 更新的临床数据支持强有力的生化控制（IGF-1 正常化），进一步增强了人们对长期使用的信心。

6. 竞争优势与市场趋势

• 帕妥索汀是一种口服小分子生长抑制素受体 2 型 (SST2)促效剂，其特性与注射缓释製剂有显着差异。
• 这种药物可望提高患者的生活质量，减少就医次数，并增强患者的治疗自主性。
• 更广泛的市场趋势，例如以患者为中心的护理、对口服疗法的偏好以及对长期疾病管理的优化，都有力地支持了帕妥昔汀的市场定位。
• 预计在罕见内分泌疾病领域更多地使用真实世界数据 (RWE) 将有助于提高支付方和处方医生在核准后的信心。

帕妥索汀的最新进展

• 2025年11月，Crinetics Pharmaceuticals宣布，首例患者已随机分配至3期CAREFNDR研究。该研究是一项多中心、随机、双盲、安慰剂对照试验，旨在评估每日一次口服帕妥昔汀治疗由分化良好的神经内分泌肿瘤引起的类癌综合征成年患者的疗效和安全性。这项3期研究建立在2期研究的积极数据之上，2期研究显示帕妥昔汀能够快速且持续地降低类癌综合征症状的频率和严重程度，包括潮红发作和排便次数增多。
• 2025年9月，Crinetics Pharmaceuticals公司宣布，美国食品药物管理局（FDA）批准了Parsonify（核准）作为第一线治疗药物，用于治疗对传统疗法反应不佳或不适合手术的成人肢端肥大症患者。 Parsonify是一种选择性生长抑制素受体2型（SST2）非胜肽促效剂，成为首个核准用于治疗成人肢端肥大症的每日一次口服药物。

《帕妥索汀销售预测及市场规模分析（2034）》报告全面深入地分析了帕妥索汀在七个主要国家（美国、四个欧盟国家（德国、法国、义大利和西班牙））的核准适应症－肢端肥大症以及潜在适应症－恶性类癌症候群的市场状况。本报告详细分析了帕妥索汀在七个主要国家（美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本）核准预测和市场表现，研究週期为2020年至2034年。报告也详细描述了帕妥索汀在核准和潜在适应症中的具体应用。此外，本帕妥索汀市场报告还深入探讨了帕妥索汀的研发及其他相关活动，包括销售预测、作用机制、剂量和给药途径以及监管里程碑。此外，该报告还详细分析了帕妥索汀的过去和现在的市场表现、未来市场评估（包括对七个主要国家已通过核准和潜在适应症的帕妥索汀市场进行预测分析）、SWOT分析、分析师观点、市场竞争对手的全面概述，以及针对每种适应症的其他新兴治疗方法的概述。该报告还对帕妥索汀的销售额及其市场驱动因素进行了预测分析。

帕妥索汀药物概述

帕妥昔汀（商品名：Parsonify）是由Crinetics Pharmaceuticals公司研发的一种新型非胜肽生长抑制素受体2型（SST2）促效剂。它是首个用于治疗肢端肥大症的每日一次口服药物。帕妥昔汀选择性地与脑下垂体生长激素细胞上的SST2受体结合，抑制生长激素（GH）分泌，降低胰岛素样生长因子1（IGF-1）水平，从而实现生化控制，并缓解对手术反应不佳或不适合手术的成人肢端肥大症患者的头痛、关节痛、出汗、疲劳和水肿等症状。该药于2025年9月25日获得美国食品药物管理局（FDA）核准。 PATHFNDR-1和PATHFNDR-2 III期临床试验表明，帕妥昔汀能够快速且持续地使IGF-1水平恢復正常，并改善肢端肥大症症状日记所记录的症状。该药物有 20 毫克和 30 毫克两种规格的片剂，使用时需监测高血糖、低血糖和心血管不良反应。本报告涵盖帕妥索汀的销售情况、成长障碍和驱动因素、上市后状况以及在多种适应症中的核准情况。

Paltusotine 目前处于 III 期临床开发阶段，用于治疗恶性类癌症候群患者（NCT07087054）。

帕图索汀市场报告范围

本报告提供以下资讯：

• 对帕妥索汀进行全面的产品概述，包括其作用机制（MoA）、产品说明、剂量和给药方法，以及核准适应症（例如肢端肥大症）和潜在适应症（例如恶性类癌综合征）的研究和开发活动。
• 本市场报告提供了有关 Paltusotine 监管里程碑和其他开发活动的详细资讯。
• 该报告还重点介绍了帕妥索汀的成本估算和区域差异、已报告和估计的销售额，以及在美国、欧洲和日本已已通过核准和潜在适应症的研发活动。
• 帕妥索汀市场报告还涵盖专利资讯、学名药上市及其对降低成本的影响。
• 本报告包括帕托索汀在已通过核准和潜在适应症方面的当前和预测销售情况，直至 2034 年。
• 此外，也全面介绍了每种适应症的后期新兴治疗方法。
• Paltusotine 市场报告还包括对 Paltusotine已通过核准和潜在适应症的 SWOT 分析和分析师观点。

调查方法：

这份帕图索汀市场报告主要基于从内部资料库、一手和二手研究以及DelveInsight产业专家团队的内部分析中获得的数据和资讯。二级资讯来源资讯和资料来自各种印刷和非印刷管道，例如搜寻引擎、新闻网站、全球监管机构网站、行业期刊、白皮书、杂誌、书籍、行业协会、贸易入口网站以及对现有资料库的存取。

DelveInsight 对帕尔图索汀的分析观点

• 帕妥索汀的详细市场评估

本市场预测报告对帕妥索汀在七个主要市场（美国、四个欧盟国家（德国、法国、义大利、西班牙）、英国和日本）的市场状况进行了详细评估，涵盖其核准的适应症——肢端肥大症，以及潜在的适应症——恶性类癌症候群。报告的这一部分提供了帕妥索汀截至2034年的当前销售数据和预测销售数据。

• 帕妥索汀的临床评价

Paltusotine 市场报告提供了有关 Paltusotine已通过核准和潜在适应症的临床试验信息，包括研究干预措施、研究条件、实验状况以及开始和完成日期。

帕尔图索汀的竞争格局

本报告深入分析了该领域的竞争对手和市售产品，并概述了新兴产品及其预计上市日期，这些产品将推动市场出现激烈的竞争。

帕妥索汀的市场潜力和收入预测

• 帕妥索汀及其主要适应症的预期市场规模
• Paltusotine 的预计销售潜力（销售尖峰时段预测）
• 帕妥昔单抗定价策略与报销环境

帕妥索汀的竞争讯息

• 在研竞争药物数量（研发管线分析）
• 帕妥索汀与现有治疗方法相比的市场定位
• 与竞争对手相比，帕妥索汀的优势和劣势

帕妥索汀监管和商业里程碑

• 帕妥索汀的关键监管核准和预计上市时间
• 商业合作、授权协议和併购活动

帕妥索汀的临床鑑别诊断

• 与现有药物相比，帕妥索汀具有更优的疗效和安全性
• 帕图索汀的独特优势

帕图索汀市场报告要点

• 未来几年，随着帕妥索汀的广泛应用、处方笺的增加以及在多种免疫适应症中的更广泛应用，其市场格局可能会发生变化，这将推动市场规模的成长。
• Paltusotine相关企业正在开发以治疗和改善疾病状态的新方法为重点的治疗方法，以评估可能影响 paltusotine 优势的挑战和机会。
• 其他用于治疗肢端肥大症的新兴产品，以及恶性类癌症候群等潜在适应症，预计将对帕妥索汀构成激烈的市场竞争，而近期推出的后期治疗方法预计将对市场产生重大影响。
• 对监管里程碑和开发活动的详细说明，提供了帕妥索汀在已通过核准和潜在适应症中的当前开发状态。
• 分析帕妥索汀的成本、定价趋势和市场定位，以支持免疫学领域的策略决策。
• 我们对 2034 年之前帕妥索汀销售预测数据的详细分析，将透过确定帕妥索汀在已通过核准和潜在适应症中的整体情况，帮助我们的客户进行治疗组合决策流程。

目录

第一章 报告概述

2. 帕妥索汀核准适应症概述（包括肢端肥大症）和潜在适应症概述（包括恶性类癌症候群）

• 产品详情
• 帕妥索汀的临床开发
  • 帕妥索汀的临床研究
  • 帕妥索汀临床试验资讯
  • 安全性和有效性
• 其他发展活动
• 产品简介

第三章 帕妥索汀的竞争格局（已上市治疗方法）

第四章 竞争格局（后期新型帕托索汀疗法）

第五章 帕图索欣市场评估

• 帕妥索汀市场展望（已通过核准和潜在适应症）
• 对七个主要国家的分析
  • 帕妥昔单抗在七个主要国家已已通过核准和潜在适应症的市场规模
• 各国市场
  • 帕妥索汀在美国已通过核准和潜在适应症的市场规模
  • 帕妥索汀在德国的市场规模（已通过核准和潜在适应症）
  • 帕妥索汀在英国已已通过核准和潜在适应症的市场规模

第六章 帕图索钦的SWOT分析

第七章 分析师观点

第八章附录

• 参考
• 报告调查方法

第九章 DelveInsight 服务

第十章 免责声明

第十一章 关于 DelveInsight

第十二章 报告购买选项

Key Factors Driving Paltusotine Growth

1. Market Share Gains and New Patient Starts

• Paltusotine is positioned as a potential first-in-class oral therapy for acromegaly, targeting a market currently dominated by long-acting injectable somatostatin receptor ligands (SRLs).
• Strong interest from endocrinologists suggests meaningful future new patient starts, particularly among patients seeking alternatives to chronic injections.
• The oral, once-daily profile is expected to lower treatment burden and improve persistence, which could translate into faster uptake following approval.
• Crinetics Pharmaceuticals' focused commercial strategy and physician education efforts around oral disease control are expected to support early adoption.

2. Expansion Across Key Indications

• Acromegaly (Primary Indication): Paltusotine is being developed for patients with acromegaly who require chronic biochemical control, including those previously treated with injectable SRLs.
• Maintenance Therapy: The drug is well positioned as a maintenance option for biochemically controlled patients, potentially replacing injectables in stable disease.
• Broad Acromegaly Population: If approved, paltusotine may be used across a wide range of patients, including those inadequately controlled or intolerant to injections.
• Pipeline and lifecycle opportunities may include earlier-line use and long-term disease management strategies.

3. Geographic Expansion

• Paltusotine is being developed with a global commercialization outlook, initially targeting major endocrine markets such as the United States and Europe.
• Asia-Pacific represents a long-term growth opportunity, supported by increasing diagnosis rates of pituitary disorders and improving access to specialist endocrine care.
• Future geographic expansion is expected to be supported by local regulatory engagement and specialty endocrinology partnerships.

4. New Indication Approvals

• Successful regulatory approval for acromegaly would significantly broaden treatment options in a market with limited innovation over the past decade.
• Paltusotine's differentiated oral profile could reshape standard-of-care algorithms, enabling label expansion across broader patient subgroups over time.
• Additional regulatory milestones and submissions in ex-US markets would further diversify future revenue streams.

5. Strong Acromegaly Volume Momentum

• Acromegaly remains a chronic, lifelong condition, requiring sustained treatment and driving consistent therapy volumes.
• Patient and physician dissatisfaction with injections is creating latent demand for oral alternatives, supporting strong uptake potential.
• Clinical updates have reinforced robust biochemical control (IGF-1 normalization), supporting confidence in long-term use.

6. Competitive Differentiation and Market Trends

• Paltusotine's oral small-molecule somatostatin receptor type 2 (SST2) agonist profile strongly differentiates it from injectable depot formulations.
• The drug offers the potential for improved quality of life, reduced clinic visits, and greater treatment autonomy.
• Broader market trends-such as patient-centric care, preference for oral therapies, and long-term disease management optimization-strongly support Paltusotine's positioning.
• Increasing use of real-world evidence (RWE) in rare endocrine disorders is expected to reinforce payer and prescriber confidence post-approval.

Paltusotine Recent Developments

• In November 2025, Crinetics Pharmaceuticals announced the first patient had been randomized in the pivotal Phase III CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The Phase III study builds on positive Phase II data in which paltusotine demonstrated rapid and sustained reductions in the frequency and severity of carcinoid syndrome symptoms, including flushing episodes and bowel movements.
• In September 2025, Crinetics Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved PALSONIFY (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist, is now the first once-daily, oral treatment approved for adults with acromegaly.

"Paltusotine Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Paltusotine for approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome in the 7MM. A detailed picture of Paltusotine's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Paltusotine for approved and potential indications. The Paltusotine market report provides insights about Paltusotine's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Paltusotine performance, future market assessments inclusive of the Paltusotine market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Paltusotine sales forecasts, along with factors driving its market.

Paltusotine Drug Summary

Paltusotine, marketed as PALSONIFY, is a novel non-peptide somatostatin receptor type 2 (SST2) agonist developed by Crinetics Pharmaceuticals as the first once-daily oral therapy for acromegaly. It selectively binds to SST2 receptors on pituitary somatotrophs, inhibiting growth hormone (GH) secretion and reducing insulin-like growth factor 1 (IGF-1) levels, thereby achieving biochemical control and alleviating symptoms like headaches, joint pain, sweating, fatigue, and swelling in adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. FDA-approved on September 25, 2025, based on PATHFNDR-1 and PATHFNDR-2 Phase 3 trials showing rapid, durable IGF-1 normalization and symptom improvement via the Acromegaly Symptom Diary, it is available as 20 mg and 30 mg tablets with monitoring for hyperglycemia, hypoglycemia, and cardiac effects. The report provides Paltusotine's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Paltusotine is in the Phase III stage of clinical development for the treatment of patients with Malignant carcinoid syndrome (NCT07087054).

Scope of the Paltusotine Market Report

The report provides insights into:

• A comprehensive product overview including the Paltusotine MoA, description, dosage and administration, research and development activities in approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome.
• Elaborated details on Paltusotine regulatory milestones and other development activities have been provided in Paltusotine market report.
• The report also highlights Paltusotine's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Paltusotine market report also covers the patents information, generic entry and impact on cost cut.
• The Paltusotine market report contains current and forecasted Paltusotine sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Paltusotine market report also features the SWOT analysis with analyst views for Paltusotine in approved and potential indications.

Methodology:

The Paltusotine market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Paltusotine Analytical Perspective by DelveInsight

• In-depth Paltusotine Market Assessment

This Paltusotine sales market forecast report provides a detailed market assessment of Paltusotine for approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Paltusotine sales data uptil 2034.

• Paltusotine Clinical Assessment

The Paltusotine market report provides the clinical trials information of Paltusotine for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Paltusotine Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Paltusotine Market Potential & Revenue Forecast

• Projected market size for the Paltusotine and its key indications
• Estimated Paltusotine sales potential (Paltusotine peak sales forecasts)
• Paltusotine Pricing strategies and reimbursement landscape

Paltusotine Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Paltusotine Market positioning compared to existing treatments
• Paltusotine Strengths & weaknesses relative to competitors

Paltusotine Regulatory & Commercial Milestones

• Paltusotine Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Paltusotine Clinical Differentiation

• Paltusotine Efficacy & safety advantages over existing drugs
• Paltusotine Unique selling points

Paltusotine Market Report Highlights

• In the coming years, the Paltusotine market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Paltusotine companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Paltusotine's dominance.
• Other emerging products for Acromegaly; and potential indication like Malignant carcinoid syndrome are expected to give tough market competition to Paltusotine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Paltusotine in approved and potential indications.
• Analyse Paltusotine cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Paltusotine sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Paltusotine in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Paltusotine? How strong is Paltusotine's clinical and commercial performance?
• What is Paltusotine's clinical trial status in each individual indications such as Acromegaly; and potential indication like Malignant carcinoid syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Paltusotine Manufacturers?
• What are the key designations that have been granted to Paltusotine for approved and potential indications? How are they going to impact Paltusotine's penetration in various geographies?
• What is the current and forecasted Paltusotine market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Paltusotine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Paltusotine for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Paltusotine? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Paltusotine Overview in approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome

• 2.1. Product Detail
• 2.2. Paltusotine Clinical Development
  • 2.2.1. Paltusotine Clinical studies
  • 2.2.2. Paltusotine Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Paltusotine Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Paltusotine Therapies)

5. Paltusotine Market Assessment

• 5.1. Paltusotine Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Paltusotine Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Paltusotine Market Size in the United States for approved and potential indications
  • 5.3.2. Paltusotine Market Size in Germany for approved and potential indications
  • 5.3.3. Paltusotine Market Size in France for approved and potential indications
  • 5.3.4. Paltusotine Market Size in Italy for approved and potential indications
  • 5.3.5. Paltusotine Market Size in Spain for approved and potential indications
  • 5.3.6. Paltusotine Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Paltusotine Market Size in Japan for approved and potential indications

6. Paltusotine SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Paltusotine, Clinical Trial Description, 2023
• Table 2: Paltusotine, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Paltusotine's pricing and cost Assumptions
• Table 6: Paltusotine's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Paltusotine Market Size in the US, in USD million (2020-2034)
• Table 8: Paltusotine Market Size in Germany, in USD million (2020-2034)
• Table 9: Paltusotine Market Size in France, in USD million (2020-2034)
• Table 10: Paltusotine Market Size in Italy, in USD million (2020-2034)
• Table 11: Paltusotine Market Size in Spain, in USD million (2020-2034)
• Table 12: Paltusotine Market Size in the UK, in USD million (2020-2034)
• Table 13: Paltusotine Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Paltusotine's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Paltusotine Market Size in the United States, USD million (2020-2034)
• Figure 3: Paltusotine Market Size in Germany, USD million (2020-2034)
• Figure 4: Paltusotine Market Size in France, USD million (2020-2034)
• Figure 5: Paltusotine Market Size in Italy, USD million (2020-2034)
• Figure 6: Paltusotine Market Size in Spain, USD million (2020-2034)
• Figure 7: Paltusotine Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Paltusotine Market Size in Japan, USD million (2020-2034)